|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: PHC2 |
Gene summary for PHC2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | PHC2 | Gene ID | 1912 |
| Gene name | polyhomeotic homolog 2 | |
| Gene Alias | EDR2 | |
| Cytomap | 1p35.1 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | A0A0A0MSI2 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 1912 | PHC2 | S015 | Human | Liver | HCC | 2.17e-07 | 6.78e-01 | 0.2375 |
| 1912 | PHC2 | S016 | Human | Liver | HCC | 1.08e-12 | 6.45e-01 | 0.2243 |
| 1912 | PHC2 | S027 | Human | Liver | HCC | 7.37e-18 | 1.46e+00 | 0.2446 |
| 1912 | PHC2 | S028 | Human | Liver | HCC | 2.06e-29 | 1.48e+00 | 0.2503 |
| 1912 | PHC2 | S029 | Human | Liver | HCC | 1.04e-27 | 1.59e+00 | 0.2581 |
| 1912 | PHC2 | RNA-P17T-P17T-2 | Human | Lung | IAC | 4.80e-03 | 4.16e-01 | 0.3371 |
| 1912 | PHC2 | RNA-P17T-P17T-4 | Human | Lung | IAC | 3.00e-06 | 5.74e-01 | 0.343 |
| 1912 | PHC2 | RNA-P17T-P17T-6 | Human | Lung | IAC | 3.22e-02 | 3.31e-01 | 0.3385 |
| 1912 | PHC2 | RNA-P17T-P17T-8 | Human | Lung | IAC | 6.98e-03 | 3.35e-01 | 0.3329 |
| 1912 | PHC2 | RNA-P3T-P3T-1 | Human | Lung | IAC | 3.64e-03 | 4.92e-01 | 0.1829 |
| 1912 | PHC2 | RNA-P3T-P3T-4 | Human | Lung | IAC | 6.70e-07 | 6.64e-01 | 0.1859 |
| 1912 | PHC2 | RNA-P6T2-P6T2-2 | Human | Lung | IAC | 3.97e-04 | 2.01e-01 | -0.0132 |
| 1912 | PHC2 | RNA-P6T2-P6T2-3 | Human | Lung | IAC | 1.47e-07 | 2.47e-01 | -0.013 |
| 1912 | PHC2 | C21 | Human | Oral cavity | OSCC | 1.44e-06 | 3.99e-01 | 0.2678 |
| 1912 | PHC2 | C30 | Human | Oral cavity | OSCC | 1.11e-16 | 1.01e+00 | 0.3055 |
| 1912 | PHC2 | C51 | Human | Oral cavity | OSCC | 1.53e-09 | 7.04e-01 | 0.2674 |
| 1912 | PHC2 | C08 | Human | Oral cavity | OSCC | 4.19e-03 | 4.14e-02 | 0.1919 |
| 1912 | PHC2 | NEOLP-2 | Human | Oral cavity | NEOLP | 1.10e-04 | 1.95e-01 | -0.0196 |
| 1912 | PHC2 | NEOLP-3 | Human | Oral cavity | NEOLP | 2.14e-02 | 1.77e-01 | -0.0191 |
| 1912 | PHC2 | SYSMH1 | Human | Oral cavity | OSCC | 3.67e-07 | 6.92e-02 | 0.1127 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| PHC2 | SNV | Missense_Mutation | c.1928N>C | p.Glu643Ala | p.E643A | Q8IXK0 | protein_coding | deleterious(0) | probably_damaging(0.989) | TCGA-BH-A0BW-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | adriamycin | CR | |
| PHC2 | SNV | Missense_Mutation | c.1927N>A | p.Glu643Lys | p.E643K | Q8IXK0 | protein_coding | deleterious(0.01) | probably_damaging(0.985) | TCGA-BH-A0BW-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | adriamycin | CR | |
| PHC2 | SNV | Missense_Mutation | c.610N>C | p.Val204Leu | p.V204L | Q8IXK0 | protein_coding | tolerated(0.09) | benign(0.273) | TCGA-BH-A18P-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
| PHC2 | SNV | Missense_Mutation | rs773965245 | c.2095N>T | p.Arg699Trp | p.R699W | Q8IXK0 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-C8-A1HI-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| PHC2 | SNV | Missense_Mutation | c.2011N>T | p.Val671Leu | p.V671L | Q8IXK0 | protein_coding | deleterious(0) | probably_damaging(0.988) | TCGA-C8-A26V-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | tamoxiphen | CR | |
| PHC2 | SNV | Missense_Mutation | c.1862N>T | p.Ser621Leu | p.S621L | Q8IXK0 | protein_coding | deleterious(0.02) | probably_damaging(0.992) | TCGA-C8-A278-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | tamoxiphen | SD | |
| PHC2 | insertion | Frame_Shift_Ins | novel | c.199_200insTCCAGCTCATGTCTGCAAATTCTCTGTGGGGGGCGGTGGCTGGG | p.Gln67LeufsTer105 | p.Q67Lfs*105 | Q8IXK0 | protein_coding | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | ||
| PHC2 | deletion | Frame_Shift_Del | novel | c.2332delG | p.Asp778ThrfsTer19 | p.D778Tfs*19 | Q8IXK0 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| PHC2 | deletion | Frame_Shift_Del | novel | c.2009delA | p.Asn670ThrfsTer61 | p.N670Tfs*61 | Q8IXK0 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| PHC2 | SNV | Missense_Mutation | rs371688704 | c.2410C>T | p.Arg804Cys | p.R804C | Q8IXK0 | protein_coding | tolerated(0.14) | benign(0.391) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |